News

Jan 21 2021

Data Demonstrates Safety of MONARCH Platform and Effective Localization of Peripheral Nodules

REDWOOD CITY, CALIF. – January 21, 2021 – Ethicon’s* Auris Health, Inc., part of Johnson & Johnson Medical Devices**, today announced results from the world’s first prospective, multicenter study of robotic bronchoscopy. The study, called BENEFIT, evaluated the safety and feasibility of the MONARCH® Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures. Results of the study were published in CHEST, the official publication of the American College of Chest Physicians.

Jul 30 2020

U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology

New Brunswick, N.J., July 30, 2020 – Ethicon, a Johnson & Johnson Medical Devices Company*, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development.

Oct 23 2019

Data Presented at CHEST 2019 Demonstrates Efficacy of Monarch to Successfully Reach Nodules and Biopsy Tissue

NEW ORLEANS – October 23, 2019 – Auris Health, Inc. (“Auris Health”), part of Johnson & Johnson Medical Devices Companies,* today announced results from a study demonstrating the safety and feasibility of the Monarch Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures. Data from the BENEFIT study was presented in a late-breaking session at the CHEST 2019 Conference in New Orleans by Alexander C. Chen, M.D., of St. Louis, Mo.

Aug 26 2019

REDWOOD CITY – August 22, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, today announced that physicians have performed over 1,000 bronchoscopic procedures using the Monarch™ Platform. Auris gained FDA clearance for diagnostic and therapeutic bronchoscopic procedures on the Monarch Platform in the Spring of 2018.

May 21 2019

Researchers conclude the Monarch™ Platform overcomes some limitations of conventional bronchoscopic systems in diagnosing lung nodules

Redwood City, Calif. and Dallas – May 21, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies,* today announced that interim results from an independent pilot feasibility study designed to evaluate the company’s Monarch Platform were presented at the American Thoracic Society (ATS) 2019 Conference in Dallas. The Monarch Platform is a first-of-its-kind robotic technology cleared by the U.S. Food and Drug Administration (FDA) for diagnostic and therapeutic bronchoscopic procedures.

May 20 2019

Ongoing BENEFIT Study of Monarch Platform Indicates Safety, Feasibility and Successful Localization of Lung Nodules in 92% of Cases

DALLAS – May 20, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies,* today announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platform, a first-of-its-kind robotic technology cleared by the U.S. Food and Drug Administration (FDA) for diagnostic and therapeutic bronchoscopic procedures. Preliminary data from the study was presented by Alexander C. Chen, M.D., of St. Louis, Mo., at the American Thoracic Society (ATS) 2019 Conference in Dallas.

Apr 19 2019

Flagship Product Wins Gold Edison and Red Dot Awards Interactive

REDWOOD CITY, Calif. – April 19, 2019 – Auris Health, Inc., a part of Johnson & Johnson Medical Devices Companies, today announced that the Monarch Platform has been recognized with a Gold 2019 Edison Award and a Red Dot: Best of the Best Award. Both award organizations recognize the best products and innovators from around the world. Auris™ creators of the first-of-its-kind robotic endoscopy technology, is being honored for its innovative approach to revolutionizing the diagnosis of lung disease.

Nov 28 2018

Funds Will Be Used to Advance Commercialization and Development of Next-Generation Robotic Interventional Technology

REDWOOD CITY, Calif. – November 28, 2018 – Auris Health, Inc. today announced the close of a $220 million equity financing led by Partner Fund Management. New investors Wellington Management, D1 Capital Partners and Senator Investment Group and existing investors including Mithril Capital, Lux Capital and Viking Global Investors also participated in the round. The company has now raised more than $700 million to date. Funding will be used to advance the commercialization of the company’s Monarch™ Platform and the development of next-generation robotic interventional technology.

Mar 23 2018

Company’s First Application of Its Innovative Flexible Robotics Platform Is Bronchoscopy

Redwood City, Calif. – March 23, 2018 – Auris Health, Inc. ("Auris Health"), formerly known as Auris Surgical Robotics, Inc., today announced U.S. Food and Drug Administration (FDA) clearance of the company’s Monarch™ Platform, ushering in a new era of medical intervention.